Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.57 |
| ▸ | ITGB6 | P18564 | 13/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.57 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140993 | 0.92 | ITGB3 (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL20140995 | 0.92 | ITGB3 (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL30850688 | 0.92 | ITGB3 (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL20142377 | 0.92 | ITGB3 (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL20153313 | 0.91 | ITGAV (0.63) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21294633 | 0.90 | ITGB3 (0.68) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21294619 | 0.90 | ITGB3 (0.68) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL20153377 | 0.90 | ITGB3 (0.68) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL30850766 | 0.90 | ITGB3 (0.68) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL24521922 | 0.85 | ITGB3 (0.64) | ITGAVITGB3ITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |